$ENTA (Enanta Pharmaceuticals, Inc.)

$ENTA {{ '2016-09-28T20:42:16+0000' | timeago}} • Announcement

$ENTA begins Phase 1 clinical study of EDP-305, its lead farnesoid X receptor (FXR) agonist under development to treat patients with non-alcoholic steatohepatitis (NASH) or fatty liver disease. The first subjects dosed in study that will evaluate EDP-305 in healthy subjects and subjects with presumptive non-alcoholic fatty liver disease (NAFLD).

$CORE {{ '2017-09-21T13:02:10+0000' | timeago}} • Announcement

$CORE, marketers of fresh and broad-line supply solutions to convenience retail industry, has announced that it has renewed its 3-year supply chain agreement with $RAD. Core-Mark is currently providing service to approx 4,500 Rite Aid stores. Finer details of the agreement are under wraps.

$PDCO {{ '2017-09-19T21:59:10+0000' | timeago}} • Announcement

$PDCO's BoD declared a quarterly cash dividend of $0.26 per share. The dividend will be payable on, or about, Oct. 27, 2017, to shareholders of record as of the close of business on Oct. 13, 2017.

$RAD {{ '2017-09-19T15:31:35+0000' | timeago}} • Announcement

Under the amended and restated asset purchase agreement with $RAD, $WBA does not expect the transaction to have a significant impact to its adjusted EPS in FY17. $WBA also expects to realize annual synergies from the transaction of more than $300MM, which are expected to be fully realized within four years of the initial closing of the transaction.

$WBA {{ '2017-09-19T14:19:18+0000' | timeago}} • Announcement

Drugstore chain $WBA, in its fourth attempt, clinched regulatory approval to buy 1,932 stores, 3 distribution centers and related inventory from $RAD for $4.375Bil. The new deal has 250 fewer stores than the earlier deal & is lower than the previous proposal of $5.18Bil. Store purchases would begin in Oct., with completion expected in spring 2018.

$AMGN {{ '2017-09-14T19:26:48+0000' | timeago}} • Announcement

$AMGN and $AGN said the FDA has approved their Mvasi for the treatment of five types of cancer. Amgen and Allergan's bevacizumab biosimilar is also undergoing review by the European Medicines Agency, following a Marketing Authorization Application submitted in December 2016.

$AMGN {{ '2017-09-14T19:26:21+0000' | timeago}} • Announcement

$AMGN and $AGN said the FDA has approved their Mvasi (bevacizumab-awwb) for the treatment of five types of cancer. The approval was based on totality of evidence from global development program showing Mvasi is highly similar to Avastin. Mvasi is the first anti-cancer biosimilar, as well as first bevacizumab biosimilar, approved by the FDA.

$ENTA {{ '2017-09-13T14:09:33+0000' | timeago}} • Announcement

Pharmaceuticals company $ENTA has appointed Kristine Peterson to its BoD, raising the total number of directors to seven. Peterson had served as CEO of Valeritas Inc from 2009 to 2016. Earlier, she held marketing and commercial positions at Johnson & Johnson, most recently as Company Group Chair of the biotech division.

$AGN {{ '2017-09-08T19:54:30+0000' | timeago}} • Announcement

$AGN transferred all patents for its dry eye treatment drug Restasis to the St. Regis Mohawk tribe to protect the drug patents. The tribe has granted Allergan back an exclusive license for the drug. As per the agreement, the tribe will get $13.75MM as one-time payment, and potentially $15MM annually in royalties.

$VRTX {{ '2017-09-06T14:56:39+0000' | timeago}} • Announcement

$VRTX has announced the appointment of Tom Graney as SVP and CFO with effect from Sept 13, 2017.  He will report to EVP and COO Ian Smith.  Graney will be responsible for the development and execution of the financial strategies and operations of Vertex's business plans. He was the CFO and SVP of Finance and Corporate Strategy at $IRWD.

$AGN {{ '2017-08-29T10:53:21+0000' | timeago}} • Announcement

$AGN and its subsidiaries reached a settlement regarding its litigation with Famy Care Ltd. relating to the company's patent covering Restasis (Cyclosporine Ophthalmic Emulsion). All Famy Care litigation regarding Restasis patents will be dismissed and Famy Care will terminate its pending petitions for Inter Parties Review.

$VRTX {{ '2017-08-24T16:02:41+0000' | timeago}} • Announcement

Biotechnology firm $VRTX said the FDA and the European Medicines Agency have accepted its application for use of the tezacaftor/ivacaftor treatment in patients suffering from certain types of cystic fibrosis. Earlier, two phase-3 studies on the effectiveness of the drug combination had returned positive results.

$PDCO {{ '2017-08-24T13:05:12+0000' | timeago}} • Announcement

$PDCO reaffirmed its FY18 guidance and expects the GAAP earnings to be in the range of $1.90 to $2.05 per diluted share. The non-GAAP earnings would be in the range of $2.25 to $2.40 per diluted share. In 1Q18, it repurchased approx. 0.8MM shares of its outstanding common stock, with a value of $37.5MM.

$PDCO {{ '2017-08-24T12:59:27+0000' | timeago}} • Announcement

The dental wing of $PDCO, which comprises 40% of the total sales, suffered as its net sales nosedived by 6.5% to $518.8MM in 1Q18. The company expects that a broadened portfolio in the dental segment would help overcome the lean patch. The Animal Health division fared better with a net sales of $776.1MM, 1.8% higher than same period last year.

$PDCO {{ '2017-08-24T12:57:20+0000' | timeago}} • Announcement

Lower sales and higher rates of depreciation and amortization pulled back the net income of $PDCO, a medical supplies firm, to $30.8MM or $0.33 per diluted share in 1Q18 compared to $38.9MM, or $0.40 per diluted share last year. The net sales dipped by 2.1% to $1.30Bil from $1.33Bil a year ago.

$PDCO {{ '2017-08-24T10:53:06+0000' | timeago}} • Announcement

Patterson Dental, a business unit of $PDCO, and $ALGN announced a distribution agreement for $ALGN's iTero Element intraoral scanning system. This agreement expands Patterson's portfolio of CAD/CAM products with iTero scanner's proven digital technology and superior Invisalign experience and tools.

$VAR {{ '2017-08-10T14:18:35+0000' | timeago}} • Announcement

Healthcare firm $VAR appointed Michael Bruff as VP of Investor Relations, effective August 7, 2017. He replaces Spencer Sias, who retired in June. Most recently, Bruff served Dell, Inc. as SVP of North America Sales Strategy & Planning. Earlier, he held the posts of SVP and CFO of Dell's Asia Pacific and Japan Commercial Business.

$VAR {{ '2017-08-09T16:01:14+0000' | timeago}} • Announcement

$VAR has signed an agreement with Bionix Radiation Therapy to distribute Bionix brachytherapy applicators. $VAR will market the Bionix Esophageal Applicator (E-App) and the Anorectal Applicator (AR-1) in North America. These applicators are used in the treatment of various types of cancers.

$ZTS {{ '2017-08-08T18:36:56+0000' | timeago}} • Webcast

$ZTS stated that its key markets in Europe performed well in 2Q17, the UK and Germany leading with 12% and 8% operational growth respectively. The growth was driven primarily by strong Apoquel sales.

$VAR {{ '2017-08-08T15:14:15+0000' | timeago}} • Announcement

$VAR reported that a patient was treated with its HyperArc High Definition Radiotherapy, a new radiosurgery treatment, for the first time at Sacro Cuore Don Calabria Cancer Care Centre in Italy. The clinicians can now deliver more compact radiation doses on the tumors and healthy tissues are spared. HyperArc has CE mark and FDA 510(k) clearance.

$ZTS {{ '2017-08-08T15:06:46+0000' | timeago}} • Infographic

$ZTS Zoetis, Inc Segment Revenue Comparison Q2 2017

Recent Transcripts

PDCO (Patterson Companies, Inc.)
Thursday, August 24 2017 - 2:00pm
CCXI (ChemoCentryx, Inc.)
Tuesday, August 8 2017 - 9:00pm
ZTS (Zoetis Inc.)
Tuesday, August 8 2017 - 12:30pm
ENTA (Enanta Pharmaceuticals, Inc.)
Monday, August 7 2017 - 8:30pm
TXMD (TherapeuticsMD, Inc.)
Thursday, August 3 2017 - 8:30pm
SYN (Synthetic Biologics Inc.)
Thursday, August 3 2017 - 12:30pm
AGN (Allergan plc)
Thursday, August 3 2017 - 12:30pm
KTWO (K2M Group Holdings, Inc.)
Tuesday, August 1 2017 - 9:00pm
VRTX (Vertex Pharmaceuticals Incorporated)
Wednesday, July 26 2017 - 9:15pm
VAR (Varian Medical Systems, Inc.)
Wednesday, July 26 2017 - 9:00pm
UHS (Universal Health Services Inc.)
Wednesday, July 26 2017 - 1:00pm
PDCO (Patterson Companies, Inc.)
Thursday, May 25 2017 - 2:00pm
PTN (Palatin Technologies Inc.)
Tuesday, May 16 2017 - 3:00pm
CCXI (ChemoCentryx, Inc.)
Wednesday, May 10 2017 - 9:00pm
AGN (Allergan plc)
Tuesday, May 9 2017 - 12:30pm
ENTA (Enanta Pharmaceuticals, Inc.)
Monday, May 8 2017 - 8:30pm
SYN (Synthetic Biologics Inc.)
Thursday, May 4 2017 - 8:30pm
ZTS (Zoetis Inc.)
Thursday, May 4 2017 - 12:30pm
KTWO (K2M Group Holdings, Inc.)
Tuesday, May 2 2017 - 9:00pm
VRTX (Vertex Pharmaceuticals Incorporated)
Thursday, April 27 2017 - 8:30pm

AlphaGraphics you may like